The cluster of C-suite selling, while small in proportion to market cap, is a modest negative signal ahead of the upcoming FDA decision on relacorilant. Monitor for any additional insider sales or negative pre-announcements.
Drug in focus
CORT drug pipeline →Lifyorli
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Lifyorli is already approved and commercially available in the U.S. for platinum-resistant ovarian cancer (approved March 25, 2026). A decision on the Cushing's syndrome indication is expected by December 17, 2026. A Marketing Authorization Application (MAA) is also under review by the European Medicines Agency.
- Next catalyst
- PDUFA date · Dec 17, 2026 31d
What to watchThe next major catalyst is the December 17, 2026 PDUFA decision on relacorilant's NDA resubmission for Cushing's syndrome. An approval would open a large endocrinology market (currently served by Korlym, which generated ~$498M in the first nine months of 2026) and could significantly expand the drug's total addressable market beyond the already-approved ovarian cancer indication. A second CRL would be a major setback for the Cushing's franchise.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 19 $119.02entry
- T+1 · 3mo ago +1.71%α +2.55% · $121.05
- T+5 · 3mo ago +0.66%α +1.04% · $119.80
- T+20 · 2mo ago −3.50%α −2.66% · $114.86
- T+60 · 4d ago −38.07%α −36.52% · $73.71
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Corcept insiders, including the Chief Business Officer and Chief Development Officer, sold a total of $1.82M in open-market sales over a week. The CBO's $1.16M sale is the largest single transaction. While the dollar amount is modest relative to CORT's $12.7B market cap (~0.014%), the cluster of C-suite selling warrants attention, especially given the stock's strong recent performance and the company's upcoming catalyst (FDA decision on relacorilant).
Key Financial Metrics
Key Facts
- Three insiders sold a total of $1.82M in open-market sales over a week.
- Chief Business Officer Robb Gary Charles sold $1.16M on August 17.
- Chief Development Officer Guyer William sold $544K on August 10.
- Total sales represent ~0.014% of CORT's $12.7B market cap.
- The cluster includes C-suite executives, which carries more weight than director-level sales.
Financial Impact
Insider sales of $1.82M, representing 0.014% of market cap
Risk Factors
- Insider sales may signal management's view that the stock is fully valued ahead of a binary catalyst.
- The FDA decision on relacorilant (expected Q4 2026) is a high-stakes event that could drive significant volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CORT-1787119850986 |
Track record
36 reports on CORT
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202611d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202613d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20265w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers